Rua Bioscience

No stated targets, forward-work backlog, or quantitative guidance were supplied. FY22 full-year revenue was NZ$24.2k, so HY23's NZ$62.8k already exceeds the prior full year, consistent with the company's stated move into commercialisation. However, with only qualitative commentary about the German launch and Polish positioning, the release does not support any view on the slope of the H2 revenue ramp or on when operating cash flow turns. What it does support is that first domestic revenue has been recognised and that inventory has been built for the next launch; what it does not support is any judgement on run-rate economics or gross margin.

• What was the specific fair value gain (biological assets, derivative, investment revaluation?) that bridged the reported loss-to-profit swing, and is it likely to reverse?
• What is the funding plan given NZ$1.7m cash against a ~NZ$3.7m half-year burn — equity raise, debt facility, or revenue acceleration assumed?
• What is the expected ramp and gross margin profile for Germany and Poland once launched, and are there any committed orders?
• Given HY22's NZ$360.4k was labelled "other income" in the extraction, what was its nature and why has it not recurred?
• What does segmental or geographic revenue look like now that domestic sales have started?

This briefing cannot assess the specific fair value item driving the profit swing, Rua's funding runway strategy, or the commercial terms of the forthcoming German and Polish launches, because none of these are quantified in the supplied extraction.